Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Bygghemma in conjunction with the acquisition of Nordiska Fönster
Mandate

Vinge advises Bygghemma in conjunction with the acquisition of Nordiska Fönster

March 11, 2019 M&A

Vinge has advised Bygghemma Sverige AB in connection with the acquisition of Nordiska Fönster i Ängelholm AB.

Bygghemma Group is the leading online provider of home improvement products in the Nordic Region. Bygghemma Group had a turnover of approximately SEK 5 billion in 2018, its head office is located in Malmö and the company is listed on Nasdaq Stockholm. Nordiska Fönster sells quality windows and doors online and has had an annual growth of approximately 29 per cent over the last three years and had a turnover of approximately SEK 50 million in 2018.

Vinge’s team consisted of Kristian Ford together with, among others, Niklas Törnell and Emelie Svensäter Jerntorp (employment law).
 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026